Table 2b.

Details on CMV management and reactivation for recipient of pre-emptive Megalotect infusion (n=78).

Time from HSCT of CMV reactivation, median (range)	29 days (−9 – 399)
Development of CMV disease	7 (9%)
First line anti-CMV therapy
Ganciclovir	33 (42%)
Foscarnet	26 (33%)
Ganciclovir + Foscarnet	3 (3%)
Valganciclovir	16 (20%)
Need for second or third line of anti-CMV therapy	9 (11%)
Duration of anti-CMV therapy, median (range)	20 days (3–190)
Median dose of Megalotect (range)	50 UI/Kg (10–100)
Schedule
Every other day	2 (2%)
Weekly	48 (62%)
Every 2 weeks	21 (27%)
Not specified	7 (9%)
Number of administration, median (range)	3 (1–33)
Complete response to anti-CMV therapy	51 (65%)
Subsequent CMV reactivation for responders	14/51 (29%)